
Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Keywords: ARGX-110; Brentuximab vedotin; Bortezomib; Copanlisib; cutaneous T-cell lymphoma; Forodesine; Gemcitabine; HDAC inhibitors; Ipilimumab; IPH4102; Mogamulizumab; Nivolumab; NM-IL-12; Panobinostat; Pegylated liposomal doxorubicin; Pentostatin; Pralatrexate;